motixafortide (BL-8040)
Metastatic Pancreatic Adenocarcinoma
Key Facts
About BioLineRx
BioLineRx is an Israeli biopharmaceutical company dedicated to identifying, in-licensing, and developing promising therapeutic candidates, primarily in oncology. Its strategic focus is on advancing motixafortide, which has demonstrated potential in multiple clinical settings, including as a stem cell mobilizer for autologous transplantation and as a combination therapy for metastatic pancreatic cancer. The company leverages a lean operational model to advance its pipeline through clinical development and strategic partnerships.
View full company profileAbout BioLineRx
BioLineRx is an Israeli biopharmaceutical company dedicated to identifying, in-licensing, and developing promising therapeutic candidates, primarily in oncology. Its strategic focus is on advancing motixafortide, which has demonstrated potential in multiple clinical settings, including as a stem cell mobilizer for autologous transplantation and as a combination therapy for metastatic pancreatic cancer. The company leverages a lean operational model to advance its pipeline through clinical development and strategic partnerships.
View full company profileTherapeutic Areas
Other Metastatic Pancreatic Adenocarcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| CPI-613 (devimistat) + FOLFIRINOX | Rafael Holdings | Phase 3 |